Literature DB >> 22230580

Antibody against Haemophilus influenzae protein D in patients with chronic conditions causing secondary immunodeficiency.

N Hawdon1, B Biman, W McCready, M Brigden, S Malik, D Vergidis, O Kisselgoff, M Ulanova.   

Abstract

Prevalence of non-typeable Haemophilus influenzae (NTHi) in the etiology of invasive infections in immunocompromised individuals is increasing. Serum IgG antibody levels to H. influenzae protein D (PD) were significantly lower in adults suffering from chronic conditions causing secondary immunodeficiency (COPD, cancer, chronic renal failure, and diabetes) compared to age-matched healthy controls. A lack of naturally acquired antibody against this highly conserved antigen may contribute to an increased susceptibility to invasive NTHi disease. As COPD patients frequently infected with NTHi during disease exacerbations were unable to develop antibody response to PD, such defect could potentially contribute to the pathogenesis. Considering that pediatric PD-containing vaccines show protective effect against NTHi-caused otitis media, our data suggest the possibility of improving the defense against NTHi in COPD patients using immunization against PD. Although more research on the role of anti-PD antibody in protection against invasive NTHi disease is warranted, development of adult formulations of PD-based vaccines may be advantageous for prevention of severe infections in immunocompromised individuals.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22230580     DOI: 10.1016/j.vaccine.2011.12.113

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Antibody Binding and Complement-Mediated Killing of Invasive Haemophilus influenzae Isolates from Spain, Portugal, and the Netherlands.

Authors:  Elena Dudukina; Laura de Smit; Giel J A Verhagen; Arie van de Ende; José María Marimón; Paula Bajanca-Lavado; Carmen Ardanuy; Sara Marti; Marien I de Jonge; Jeroen D Langereis
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

2.  Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial.

Authors:  Kerry-Ann F O'Grady; Keith Grimwood; Allan Cripps; Edward K Mulholland; Peter Morris; Paul J Torzillo; Nicholas Wood; Heidi Smith-Vaughan; Amber Revell; Andrew Wilson; Peter Van Asperen; Peter Richmond; Ruth Thornton; Sheree Rablin; Anne B Chang
Journal:  Trials       Date:  2013-09-05       Impact factor: 2.279

Review 3.  Lower airway colonization and inflammatory response in COPD: a focus on Haemophilus influenzae.

Authors:  Lydia J Finney; Andrew Ritchie; Elizabeth Pollard; Sebastian L Johnston; Patrick Mallia
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-10-13

4.  Relationships between Mucosal Antibodies, Non-Typeable Haemophilus influenzae (NTHi) Infection and Airway Inflammation in COPD.

Authors:  Karl J Staples; Stephen Taylor; Steve Thomas; Stephanie Leung; Karen Cox; Thierry G Pascal; Kristoffer Ostridge; Lindsay Welch; Andrew C Tuck; Stuart C Clarke; Andrew Gorringe; Tom M A Wilkinson
Journal:  PLoS One       Date:  2016-11-29       Impact factor: 3.240

5.  Australian Aboriginal Children with Otitis Media Have Reduced Antibody Titers to Specific Nontypeable Haemophilus influenzae Vaccine Antigens.

Authors:  Ruth B Thornton; Lea-Ann S Kirkham; Karli J Corscadden; Selma P Wiertsema; Angela Fuery; B Jan Jones; Harvey L Coates; Shyan Vijayasekaran; Guicheng Zhang; Anthony Keil; Peter C Richmond
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

6.  Invasive Disease Caused by Nontypeable Haemophilus influenzae.

Authors:  Jeroen D Langereis; Marien I de Jonge
Journal:  Emerg Infect Dis       Date:  2015-10       Impact factor: 6.883

7.  Haemophilus influenzae Non-type b Infection in an Adult Patient with Systemic Lupus Erythematosus.

Authors:  Yasuhiro Hasegawa; Yoshiyuki Arinuma; Sumiaki Tanaka; Toshihiro Tono; Tomoki Tanaka; Takumi Muramatsu; Junichi Kondo; Yu Matsueda; Takayuki Hoshiyama; Tatsuhiko Wada; Yoko Takayama; Kunihiro Yamaoka
Journal:  Intern Med       Date:  2020-08-04       Impact factor: 1.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.